European Archives - Page 236 of 1391 - European Medical Journal

Allergic Rhinitis Increases Risk of Depression and Anxiety

The study suggests that the inflammatory processes central to AR may also affect the brain, potentially leading to mood disturbances through mechanisms such as elevated cytokines or histamine imbalance.

Combination Therapy Shows Promise in ‘Cold’ Soft Tissue Sarcoma Trial

A new clinical trial offers insight into tackling one of the biggest challenges in soft tissue sarcomas….

Europe Urged to Improve Newborn Biliary Atresia Screening

Biliary atresia is the most common surgical cause of cholestatic jaundice in infants and the leading reason for paediatric liver transplants

Saliva Testing Identifies Early Risk for Cancer and Chronic Diseases

Saliva-based DNA markers could predict cancer, heart disease, and more—offering a non-invasive future for early diagnosis.

AI Enhances Efficiency and Accuracy in Tumour Biomarker Testing

A new study highlights the clinical promise of AI-driven IHC prediction models, showing high accuracy and diagnostic concordance with conventional pathology.

MVA-BN Vaccine Offers Safe Mpox Protection in At-Risk Groups

A German multicentre study shows MVA-BN vaccination is safe and moderately effective in preventing mpox, especially in HIV-negative individuals.

Dupilumab Linked to Increased Psoriasis Risk in Atopic Dermatitis

Given dupilumab’s well-documented benefits in controlling moderate to severe AD, clinicians are advised to weigh this potential risk carefully against its therapeutic advantages.

Widespread Ignorance of Alcohol’s Cancer Risk

Despite alcohol being a leading preventable cause of cancer in the United States, public awareness of its cancer risk remains strikingly low, according to a new study.

Critical Management of Neurocysticercosis with Hydrocephalus

Neurocysticercosis, a parasitic brain infection caused by the larvae of Taenia solium that leads to cysts in the central nervous system…

Minimally Invasive Treatment for Benign Prostatic Hyperplasia

Importantly, 30% mean reductions in prostate volume were sustained up to 18 months post-procedure.